Compounded Semaglutide vs Semaglutide: What's the Difference?

Compounded semaglutide is semaglutide prepared by a licensed 503A or 503B compounding pharmacy under an individual physician's prescription. It is not FDA-approved, and the FDA has not reviewed it for safety, efficacy, or manufacturing quality.

Brand-name semaglutide products — Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management) — are manufactured by Novo Nordisk and have undergone the full FDA approval process. Compounded semaglutide uses the same active molecule but is not the same product and does not carry those approvals.

Compounding pharmacies operate legally under federal law to meet individual patient needs that brand-name products cannot. Access expanded significantly during the semaglutide drug shortage, when demand for Ozempic and Wegovy outpaced supply. The FDA has since removed semaglutide from the drug shortage list (FDA Drug Shortages, 2025), which affects the legal basis for large-scale compounding at 503B outsourcing facilities.

What compounded semaglutide offers: the same active ingredient and the same mechanism of action. What it does not offer: FDA review of manufacturing, clinical trial data specific to the compounded formulation, or the brand-name product's quality-control documentation.

The main differences between compounded and brand-name semaglutide are FDA approval status, manufacturing oversight, delivery form, and insurance coverage.

FDA approval means the agency reviewed the drug's safety, efficacy, manufacturing process, and labeling before it reached patients. Compounded semaglutide bypasses that review. The 503A and 503B frameworks require pharmacies to meet United States Pharmacopeia (USP) sterility and quality standards, but those standards are not equivalent to FDA drug approval.

Compounded semaglutide works through the same mechanism as brand-name semaglutide — it binds GLP-1 receptors, slows gastric emptying, and reduces appetite — but it has not been studied in its own clinical trials.

The clinical evidence on semaglutide's effectiveness comes from the STEP trials for Wegovy. STEP-1 reported mean body weight reduction of about 15% over 68 weeks in adults with obesity without type 2 diabetes (Wilding et al., N Engl J Med, 2021). That evidence applies to Wegovy — not to compounded semaglutide.

What can be reasonably said: if the active ingredient in a compounded version is correctly formulated and dosed, the mechanism of action is the same. That if is the central variable. Compounded semaglutide products have varied in quality. The FDA has taken action against pharmacies for products that failed potency testing, contained adulterants, or were mislabeled (FDA actions on compounded semaglutide, 2024).

A correctly formulated compounded semaglutide from a reputable 503A pharmacy should behave like semaglutide. The challenge is verifying formulation quality without FDA review.

The primary risk of compounded semaglutide is not FDA-approved manufacturing oversight. Beyond that, the side effect profile and contraindications are the same as brand-name semaglutide.

Manufacturing quality. Compounded products are not reviewed by the FDA for potency, sterility, or consistency. The FDA has taken action against compounders that produced underdosed, overdosed, or contaminated semaglutide products.

Common side effects. Nausea, vomiting, diarrhea, and constipation are the most frequently reported side effects of semaglutide. They are most common during dose escalation and typically improve at a stable dose (Wilding et al., 2021).

Contraindications. Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies. It is not used in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). It is also not appropriate for patients with a history of pancreatitis, and it should not be used during pregnancy, breastfeeding, or when actively trying to conceive.

Who evaluates these risks. A US-licensed physician reviews a patient's history before prescribing any semaglutide product — compounded or brand-name. The assessment process is the same.

Getting compounded semaglutide through a pharmacy requires a valid prescription from a licensed physician. The process cannot be shortcut: a pharmacy cannot legally dispense compounded semaglutide without one.

The standard path is an online assessment with a licensed physician, who reviews your health history, determines whether semaglutide is appropriate, and writes the prescription if it is. The prescription goes to a licensed 503A compounding pharmacy, which prepares and ships the medication directly to you.

Protocol MD offers compounded semaglutide through a physician-led program: an online assessment, review by a US-licensed physician, and ongoing management from a medical team that includes GLP-1 side effect monitoring.

What to look for in a compounded semaglutide pharmacy: PCAB (Pharmacy Compounding Accreditation Board) accreditation, 503A licensure, state pharmacy board compliance, and COA (certificate of analysis) documentation for potency and sterility testing.

Compounded semaglutide uses the same active molecule as Ozempic and Wegovy but is not FDA-approved. It requires a physician prescription, is filled at a licensed 503A pharmacy, and carries the same side effect and contraindication profile as brand-name semaglutide. A physician determines which option is appropriate for a given patient.